Small Molecule Drug for Targeting Resistant Prostate Cancer07323New CPPI-derived small molecules act as nuclear androgen receptor degraders, suppressing resistant prostate cancer in AR-positive tumors.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyTagsLife ScienceOncologyLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsTimothy James CasadJoel B. NelsonZhou WangDate Submitted2025-09-02
Mitoparib: A Mitochondrial PARP Inhibitor that Counteracts Metabolic Stress03916Mitochondria-targeted PARP inhibitor that preserves mitochondrial NAD+, preventing stress-induced necrosis without hindering nuclear DNA repair.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsHulya BayirRobert B. ClarkTanja KrainzTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2016-04-23
Next Generation Targeted Nitroxides05064Nitroxide-based lipids curb lipid peroxidation to mitigate ferroptosis, aiming at ischemia injury, AKI, and neuroprotection.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasEndocrinology and Metabolic DiseasesNephrologyTherapeutic IndicationsAcute Kidney Injury (AKI)Lead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsPeter WipfDate Submitted2019-07-20CollectionsCardiometabolic
Novel Class Therapeutic Psychedelics05753Novel clavine psychedelics: total synthesis enables SAR-driven development of non-hallucinogenic, CNS-targeting therapeutic candidates.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasMental and Behavioral HealthTherapeutic IndicationsDepressionLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsEthan James PazurNikhil Rushi TaskerPeter WipfTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2021-07-02
Novel Carbamates as Treatment for Tinnitus03415Potent, selective carbamates target KCNQ2/3 channels to reduce tinnitus and potentially treat epilepsy, via auditory synapse modulation.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOtolaryngologyLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsAthanassios TzounopoulosPeter WipfTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2014-10-03
Novel Mitochondrial Targeting Nitroxides for Radioprotection and the Treatment of Associated Pathologies02662Mitochondria-targeted nitroxide JP4-039 shields tissue from ROS and radiation, aiding healing with topical/oral delivery.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasEndocrinology and Metabolic DiseasesLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsPeter WipfTechnology Readiness Level4. Pre-clinical developmentDate Submitted2012-04-11CollectionsRegenerative MedicineCardiometabolic
Novel Thiadiazines as Heat Shock Protein Modulators and Anti-Huntington Disease Therapeutic Agents05177Novel thiadiazine modulators target Hsp70, offering potential Huntington and neurodegenerative disease therapies via protein homeostasis regulation.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsJeffrey L. Brodsky Ph.D.Linh Khai NgoLeila TerrabTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2019-11-20
Novel Selective Kv7 Channel Modulators06017Novel chemotypes selectively modulate Kv7.2 channels, enabling safer, isoform‑specific treatments for epilepsy, tinnitus, and other channelopathies.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceCardiovascularTagsLife ScienceLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsPeter WipfTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2022-05-02CollectionsCardiometabolic
HDAC Inhibitors as Anticancer Agents05372HDAC-inhibiting chromane-based compounds offer selective anticancer and potential neurodegenerative therapies, advancing epigenetic cancer treatment.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsShikha Singh ChauhanDesirae Lynn CrockerMichael James HoughtonTechnology Readiness Level2. Initial proof of concept, in-vitroDate Submitted2020-05-19
Novel carbamates as treatment for tinnitus04567Novel carbamates target auditory K-channels (KCNQ2/3) to reduce tinnitus and potentially treat epilepsy with potent, selective action.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceOtolaryngologyTagsAgingRare diseaseLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsPeter WipfTechnology Readiness Level3. Initial proof of concept, in-vivoDate Submitted2018-03-27CollectionsRare Diseases
Synthesis and Structure-Activity Relationships of Benzothienothiazepinone Inhibitors of Protein Kinase D02314Five to tenfold PKD1 inhibition gains with benzothienothiazepinone/pyrimidine scaffolds; aids anti-cancer tool design and PKD research.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsQiming Jan WangPeter WipfDate Submitted2010-10-06
Novel Calcium Channel Agonist to Treat Lambert Easton02841A novel, use-dependent calcium channel agonist GV-58 shows promise for Lambert-Eaton syndrome, boosting neurotransmitter release with fewer side effects.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasNeuroscienceTherapeutic IndicationsParkinson's DiseaseAmyotrophic lateral sclerosis (ALS)Lead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsMary LiangStephen D. MerineyPeter WipfDate Submitted2012-07-23
MMS350: A Novel Bifunctional Sulfoxide with Radioprotective Effects02601MMS350: bifunctional oxetane sulfoxide system boosting drug solubility and providing radiation protection with low toxicity.Technology TypeTherapeutic ModalityTechnology SubtypeSmall MoleculeTherapeutic AreasOncologyLead InventorPeter WipfDepartmentChemistryAll Tech InnovatorsMichael W. Epperly Ph.D.Joel S. Greenberger M.D.Melissa M. SprachmanDate Submitted2011-10-20
